Glial Fibrillary Acidic Protein (GFAP*)

GFAP: Understanding Glial Fibrillary Acidic Protein

Glial Fibrillary Acidic Protein (GFAP) is a crucial class-III intermediate filament predominantly found in astrocytic glial cells within the central nervous system (CNS). These astrocytes play vital roles in supporting, nurturing, and signaling neuronal functions.

GFAP, with a monomeric weight of approximately 55kD, has the capability to form homodimers and heterodimers. It can polymerize not only with similar type III proteins but also with neurofilament protein (such as Neurofilament Light), contributing to the structural integrity of the CNS.

In addition to its role in maintaining CNS architecture, GFAP is involved in essential processes such as cell communication and the functioning of the blood-brain barrier.

This multifunctional protein serves as a potential biomarker associated with various neurological conditions.

Studies have shown correlations between GFAP levels and conditions like traumatic brain injury, stroke, and brain tumors. Furthermore, alterations in GFAP expression have been observed in neurodevelopmental disorders such as Down syndrome, as well as psychiatric conditions including schizophrenia, bipolar disorder, and depression.

Understanding GFAP and its implications in neurological health and disease is essential for advancing diagnostic and therapeutic strategies, ultimately improving patient outcomes and quality of life.

*Banyan GFAP™ is a registered trademark of Banyan Biomarkers

Applications and Intended Use

The Simoa® GFAP Advantage PLUS assay is an ultra-sensitive immunoassay intended for the measurement of GFAP in human CSF and EDTA plasma samples.

Compatible Instruments

Advantage PLUS: HD-X

Kit Contents

The assay kit includes all necessary reagents and controls to perform 96 tests, making it easy to use and compatible with various sample types.

Safety Data Sheets

Certificates Of Analysis